- Home
- MGRC vs VRDN Comparison
MGRC vs VRDN Comparison
Compare MGRC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGRC | VRDN |
|---|---|---|
| Founded | 1979 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MGRC | VRDN |
|---|---|---|
| Price | $107.46 | $32.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $143.00 | $39.73 |
| AVG Volume (30 Days) | 128.4K | ★ 1.7M |
| Earning Date | 10-23-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.90 | N/A |
| Revenue | ★ $931,222,000.00 | $70,789,000.00 |
| Revenue This Year | $5.46 | $26,477.48 |
| Revenue Next Year | $4.31 | $6.23 |
| P/E Ratio | $18.31 | ★ N/A |
| Revenue Growth | 4.78 | ★ 23340.07 |
| 52 Week Low | $94.99 | $9.90 |
| 52 Week High | $129.93 | $34.04 |
Technical Indicators
Market Signals| Indicator | MGRC | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 54.41 | 58.73 |
| Support Level | $105.78 | $31.20 |
| Resistance Level | $109.41 | $33.52 |
| Average True Range (ATR) | 2.87 | 1.30 |
| MACD | 0.76 | -0.32 |
| Stochastic Oscillator | 64.02 | 47.64 |
Price Performance
Historical ComparisonAbout MGRC McGrath RentCorp
McGrath RentCorp is a rental company. It is comprised of four reportable business segments namely Modular building segment (Mobile Modular); Portable storage container segment (Portable Storage); Electronic test equipment segment (TRS-RenTelco); and its classroom manufacturing business selling modular buildings used as classrooms in California (Enviroplex). The company generates its revenues majorily from the rental of its equipment on operating leases with sales of equipment occurring in the normal course of business.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).